131 related articles for article (PubMed ID: 9579637)
1. Research and development commitments in an integrated plasma collection and plasma fractionation environment.
Radosevich M
Semin Thromb Hemost; 1998; 24(2):157-61. PubMed ID: 9579637
[TBL] [Abstract][Full Text] [Related]
2. Chromatographic removal of viruses from plasma derivatives.
Burnouf T
Dev Biol Stand; 1993; 81():199-209. PubMed ID: 8174804
[TBL] [Abstract][Full Text] [Related]
3. Purification of intravenous immunoglobulin G from human plasma--aspects of yield and virus safety.
Buchacher A; Iberer G
Biotechnol J; 2006 Feb; 1(2):148-63. PubMed ID: 16892245
[TBL] [Abstract][Full Text] [Related]
4. New trends in plasma fractionation and plasma products.
Burnouf T
Vox Sang; 1994; 67 Suppl 3():251-3. PubMed ID: 7975504
[No Abstract] [Full Text] [Related]
5. Strategy for purification of coagulation factor concentrates.
Clark DB; Drohan WN; Miekka SI; Katz AJ
Ann Clin Lab Sci; 1989; 19(3):196-207. PubMed ID: 2658728
[TBL] [Abstract][Full Text] [Related]
6. Intravenous immunoglobulin G: trends in production methods, quality control and quality assurance.
Radosevich M; Burnouf T
Vox Sang; 2010 Jan; 98(1):12-28. PubMed ID: 19660029
[TBL] [Abstract][Full Text] [Related]
7. [Viral safety considerations in immunoglobulin preparations].
Gómez Manzano P; Escrivá CA; Salmerón García F; Alonso Verduras C
Sangre (Barc); 1997 Jun; 42(3):199-203. PubMed ID: 9381262
[No Abstract] [Full Text] [Related]
8. The development of plasma derivatives in Australia.
Schiff P
Vox Sang; 1972; 23(1):38-43. PubMed ID: 4628156
[No Abstract] [Full Text] [Related]
9. [Viral safety: European and French directives].
Rossi F; Legras JF
Ann Med Interne (Paris); 2000 May; 151 Suppl 1():1S55-61. PubMed ID: 10896992
[TBL] [Abstract][Full Text] [Related]
10. Economical impact of plasma fractionation project in Iran on affordability of plasma-derived medicines.
Cheraghali AM; Aboofazeli R
Transfus Med; 2009 Dec; 19(6):363-8. PubMed ID: 19778319
[TBL] [Abstract][Full Text] [Related]
11. Notes on plasma derivative production in the Federal Republic of Germany.
Schwick HG
Vox Sang; 1972; 23(1):44. PubMed ID: 5081013
[No Abstract] [Full Text] [Related]
12. Note for guidance. Guidelines for medicinal products derived from human blood and plasma. Committee for Proprietary Medicinal Products: Ad Hoc Working Party on Biotechnology/Pharmacy and Working Party on Safety Medicines.
Biologicals; 1992 Jun; 20(2):159-64. PubMed ID: 1389112
[No Abstract] [Full Text] [Related]
13. Reducing the risk of infection from plasma products: specific preventative strategies.
Burnouf T; Radosevich M
Blood Rev; 2000 Jun; 14(2):94-110. PubMed ID: 11012252
[TBL] [Abstract][Full Text] [Related]
14. Affinity chromatography to remove viruses during preparation of plasma derivatives.
Lawrence JE
Dev Biol Stand; 1993; 81():191-7. PubMed ID: 8174803
[TBL] [Abstract][Full Text] [Related]
15. [Plasma fractionation. Progress, problems and perspectives].
Burnouf T
Ann Pharm Fr; 1994; 52(3):124-36. PubMed ID: 7998759
[TBL] [Abstract][Full Text] [Related]
16. Viral safety of coagulation factor concentrates.
Mannucci PM
Dev Biol Stand; 1993; 81():253-9. PubMed ID: 8174811
[No Abstract] [Full Text] [Related]
17. Product delivery in the developing world: options, opportunities and threats.
Farrugia A
Haemophilia; 2004 Oct; 10 Suppl 4():77-82. PubMed ID: 15479376
[TBL] [Abstract][Full Text] [Related]
18. [Modern methods for the manufacture of therapeutic coagulation factors].
Fuhge P; Gratz P; Geiger H
Behring Inst Mitt; 1986 Feb; (79):165-76. PubMed ID: 3087341
[TBL] [Abstract][Full Text] [Related]
19. New trends in plasma fractionation.
Steinbuch M
Haematologia (Budap); 1983; 16(1-4):39-51. PubMed ID: 6207083
[No Abstract] [Full Text] [Related]
20. Chromatography in plasma fractionation: benefits and future trends.
Burnouf T
J Chromatogr B Biomed Appl; 1995 Feb; 664(1):3-15. PubMed ID: 7757237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
